MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze ALKS →
    • FindStock Picks / Stock Screener
    • Value · ALKSIntrinsic Value Calculator
    • Invest · ALKSInvestment Case
    • Hold · ALKS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ALKS

ALKS

Alkermes plc

$45.73
0.04
 (0.09%)
Exchange:  NASDAQ
Market Cap:  7.672B
Shares Outstanding:  164.703M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – Specialty & GenericView industry performance
   
CEO:  Blair Jackson
Full Time Employees:  2050
Address: 
Connaught House
Dublin
DU
D04 C5Y6
IE
Website:  http://www.alkermes.com
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
ALALKS logoALKSAlkermes plc7.7B113—2.1%
AMAMRX logoAMRXAmneal Pharmaceuticals, Inc.6.8B43.218.913.4%
LNLNTH logoLNTHLantheus Holdings, Inc.6.6B23.918.711.0%
ININDV logoINDVIndivior Pharmaceuticals Inc4.5B9.79.095.4%
BHBHC logoBHCBausch Health Companies Inc.3.1B—1.814.4%
RDRDY logoRDYDr. Reddy's Laboratories Limited12.2B40.223.14.8%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/05 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,663,4051,557,6321,475,899
Gross Profit1,410,3681,312,3011,279,442
EBITDA519,478494,861330,892
Operating Income414,122420,636253,956
Net Income355,757367,070241,664

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,136,2232,055,5672,486,993
Total Liabilities933,537590,590667,698
Total Stockholders Equity1,202,6861,464,9771,819,295
Total Debt372,18575,53869,999
Cash and Cash Equivalents457,469291,146588,360

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow401,353439,124520.799
Capital Expenditure-48,048-33,4840
Free Cash Flow353,305405,640520.799
Net Income355,757367,070241,664
Net Change in Cash164,996-166,323828.700

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)2,479,165.453Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)2,869,277.295Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)2,618,996.573Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)726,708.658Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)863,453.317Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)775,723.370Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)460,062.605Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)555,793.884Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)494,376.494Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,146,679.513Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,327,116.546Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,211,355.100Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)2.930Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)3.290Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)2.730Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)6Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)5Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
1.558B  ?P/S
 (TTM)
: 
4.56
?Net Income
 (TTM)
: 
367.07M  ?P/E
 (TTM)
: 
112.51
?Enterprise Value
 (TTM)
: 
8.667B  ?EV/FCF
 (TTM)
: 
39.1
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
3.72%  ?ROIC
 (TTM)
: 
2.12%
?Net Debt
 (TTM)
: 
-676.13M  ?Debt/Equity
 (TTM)
: 
0.87
?P/B
 (TTM)
: 
4.18  ?Current Ratio
 (TTM)
: 
2.3

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates ALKS intrinsic value between $34.33 – $40.64 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate ALKS Intrinsic Value

Common questions about ALKS valuation

Is Alkermes plc (ALKS) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Alkermes plc (ALKS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ALKS a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ALKS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ALKS’s P/E ratio?

You can see ALKS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ALKS?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ALKS a good long-term investment?

Whether ALKS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Alkermes plc

  • Alkermes plc intrinsic value calculatorEstimate what the business is worth
  • Alkermes plc 5-year outlookWhat has to go right, and what could go wrong
ALKS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.09
MarketSnap

Trading Metrics:

Open: 46.23   Previous Close: 45.69
Day Low: 44.58   Day High: 47.01
Year Low: 27   Year High: 55.67
Price Avg 50: 43.92   Price Avg 200: 40.61
Volume: 599792   Average Volume: 1.915M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

What Alkermes (ALKS) Said on Its Q3 Earnings Call
03-11-2026 13:17
What Alkermes (ALKS) Said on Its Q3 Earnings Call
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story
29-10-2026 14:39
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story
Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue
20-10-2026 03:53
Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won
21-09-2026 09:22
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won
California State Teachers Retirement System Increases Holdings in Alkermes plc $ALKS
15-09-2026 03:26
California State Teachers Retirement System Increases Holdings in Alkermes plc $ALKS
Alkermes Q2 Earnings Call Highlights
28-07-2026 10:06
Alkermes Q2 Earnings Call Highlights

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze ALKS →
    • FindStock Picks / Stock Screener
    • Value · ALKSIntrinsic Value Calculator
    • Invest · ALKSInvestment Case
    • Hold · ALKS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read